ANI Pharmaceuticals Inc (NASDAQ:ANIP) Major Shareholder Sells $1,423,962.00 in Stock

Share on StockTwits

ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 19,860 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $71.70, for a total transaction of $1,423,962.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Meridian Venture Partners Ii L also recently made the following trade(s):

  • On Tuesday, August 13th, Meridian Venture Partners Ii L sold 61,697 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.64, for a total transaction of $4,419,973.08.

ANI Pharmaceuticals stock opened at $67.09 on Friday. The firm’s fifty day moving average price is $80.45 and its 200-day moving average price is $70.60. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The stock has a market cap of $847.24 million, a P/E ratio of 14.55 and a beta of 2.17. ANI Pharmaceuticals Inc has a fifty-two week low of $36.92 and a fifty-two week high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.26. The firm had revenue of $54.36 million for the quarter, compared to analysts’ expectations of $55.20 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the company posted $1.13 EPS. On average, analysts predict that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current year.

ANIP has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 target price (up from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $89.00.

Several institutional investors have recently bought and sold shares of ANIP. Tower Research Capital LLC TRC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $32,000. Financial Gravity Wealth Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $54,000. Quantamental Technologies LLC raised its position in shares of ANI Pharmaceuticals by 169.4% during the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 542 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 237.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 559 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 64.22% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Story: Insider Trading

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Southwest Airlines Co to Issue Quarterly Dividend of $0.18
Southwest Airlines Co to Issue Quarterly Dividend of $0.18
Cohen and Steers Global Income Builder  Announces Monthly Dividend of $0.06
Cohen and Steers Global Income Builder Announces Monthly Dividend of $0.06
Peabody Energy Co.  to Issue Dividend Increase – $0.15 Per Share
Peabody Energy Co. to Issue Dividend Increase – $0.15 Per Share
Dillard’s  PT Lowered to $37.00 at JPMorgan Chase & Co.
Dillard’s PT Lowered to $37.00 at JPMorgan Chase & Co.
Morgan Stanley Cuts CMS Energy  Price Target to $59.00
Morgan Stanley Cuts CMS Energy Price Target to $59.00
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR  to Sell
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR to Sell


 
© 2006-2019 Zolmax.